An examination of neurocognition and theory of mind as predictors of engagement with a tailored digital therapeutic in persons with serious mental illness.

dc.contributor.author

Halverson, Tate F

dc.contributor.author

Browne, Julia

dc.contributor.author

Thomas, Samantha M

dc.contributor.author

Palenski, Paige

dc.contributor.author

Vilardaga, Roger

dc.date.accessioned

2022-12-06T20:25:22Z

dc.date.available

2022-12-06T20:25:22Z

dc.date.issued

2022-06

dc.date.updated

2022-12-06T20:25:20Z

dc.description.abstract

There is an increasing interest in the development and implementation of digital therapeutics (apps) in individuals with serious mental illness (SMI). However, there is limited understanding of the role of neurocognition and social cognition on engagement with apps. The present study is a secondary analysis of a pilot randomized controlled trial (N = 62) comparing a tailored digital intervention to treat tobacco use disorder in individuals with SMI to a standard of care digital intervention for the general population. The purpose of this study was to examine the impact of neurocognition, social cognition, and clinical characteristics on indices of app engagement in users of the tailored app compared to users of the standard of care app. Correlational analyses demonstrated that individuals with low levels of neurocognition and social cognition engaged more often and for longer duration with the tailored app compared to the standard of care app. In a series of multilevel zero-inflated negative binomial models, assignment to the tailored app remained the most robust predictor of app interactions (Risk Ratio [RR] = 1.72; p < .01), duration of app use (RR = 6.47; p < .01), and average length of interaction (RR = 2.70; p < .01), after adjusting for key demographic and clinical characteristics, and two measures of cognition. This is one of the first studies to demonstrate that digital therapeutics can be designed to mitigate the impact of neurocognition and social cognition on device engagement in SMI populations. Recommendations are made to advance the use of new analytic models to uncover patterns of engagement with digital therapeutics.

dc.identifier

S2215-0013(22)00001-4

dc.identifier.issn

2215-0013

dc.identifier.issn

2215-0013

dc.identifier.uri

https://hdl.handle.net/10161/26349

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Schizophrenia research. Cognition

dc.relation.isversionof

10.1016/j.scog.2022.100236

dc.subject

Cigarette

dc.subject

Cognition

dc.subject

Digital therapeutic

dc.subject

Serious mental illness

dc.subject

Tobacco

dc.subject

mHealth

dc.title

An examination of neurocognition and theory of mind as predictors of engagement with a tailored digital therapeutic in persons with serious mental illness.

dc.type

Journal article

duke.contributor.orcid

Vilardaga, Roger|0000-0002-7252-4343|0000-0003-1403-5063

pubs.begin-page

100236

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Psychiatry & Behavioral Sciences

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Duke Institute for Brain Sciences

pubs.organisational-group

Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences

pubs.publication-status

Published

pubs.volume

28

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
An examination of neurocognition and theory of mind as predictors of engagement with a tailored digital therapeutic in perso.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format